The purpose of this research study is to see if adding the PARP inhibitor olaparib concurrently with SRS followed by immunotherapy (durvalumab) and chemotherapy will lead to better control of breast cancer that has spread to the brain better than the standard approach.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
Florida, New York, North Carolina (Statewide), Ohio
Colette Shen
LCCC - Clinical Trials
Clinical or Medical
Interventional
Brain, Head, Nervous System
Cancer (Brain and Other Nervous System, Breast)
20-2970
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
